

Julia Brandts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2941357/publications.pdf>

Version: 2024-02-01

10
papers

169
citations

1307594

7
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

239
citing authors

#	ARTICLE	IF	CITATIONS
1	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From ADA VINCI. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 941-953.	2.6	6
2	A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 325, 46-56.	0.8	18
3	Clinical implications and outcomes of the ORION Phase III Trials. <i>Future Cardiology</i> , 2021, 17, 769-777.	1.2	19
4	Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1831-1843.	2.8	32
5	Apabetalone – A BET protein inhibition in cardiovascular disease and Type 2 diabetes. <i>Future Cardiology</i> , 2020, 16, 385-395.	1.2	6
6	Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 763-770.	4.1	19
7	Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies. <i>Current Opinion in Lipidology</i> , 2020, 31, 182-186.	2.7	13
8	Low Density Lipoprotein Cholesterol – Lowering Strategies and Population Health. <i>Circulation</i> , 2020, 141, 873-876.	1.6	39
9	Familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2020, 31, 111-118.	2.7	11
10	PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2019, 21, 40.	4.8	6